LEVALLORPHAN TARTRATE
|
- $95.3 - $1260
- Product name: LEVALLORPHAN TARTRATE
- CAS: 71-82-9
- MF: C19H25NO.C4H6O6
- MW: 433.498
- EINECS:200-767-3
- MDL Number:MFCD00210203
- Synonyms:17-allyl-morphinan-3-otartrate(1:1)(salt) ;4a-iminoethanophenanthren-6-ol,11-allyl-1,3,4,9,10,10a-hexahydro-2h-1tar ;levallorphanhydrogentartrate ;levallorphantartrate ;levallorphinetartrate ;l-levallorphantartrate ;lorfan ;LEVALLORPHAN TARTRATE OPIOID RECEPTOR AN TAG
3 prices
Selected condition：
Brand
- American Custom Chemicals Corporation
- Sigma-Aldrich
- TRC
Package
- 5MG
- 10mg
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberAPI0008342
- Product descriptionLEVALLORPHAN TARTRATE SALT 95.00%
- Packaging5MG
- Price$647.82
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product numberL121
- Product descriptionLevallorphan tartrate salt ≥98% (HPLC), powder
- Packaging5mg
- Price$95.3
- Updated2024-03-01
- Buy
- ManufacturerTRC
- Product numberL330950
- Product descriptionLevallorphan tartrate salt
- Packaging10mg
- Price$1260
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| American Custom Chemicals Corporation | API0008342 | LEVALLORPHAN TARTRATE SALT 95.00% | 5MG | $647.82 | 2021-12-16 | Buy |
| Sigma-Aldrich | L121 | Levallorphan tartrate salt ≥98% (HPLC), powder | 5mg | $95.3 | 2024-03-01 | Buy |
| TRC | L330950 | Levallorphan tartrate salt | 10mg | $1260 | 2021-12-16 | Buy |
Properties
Melting point :176-177°
alpha :D16 -39°
solubility :H2O: soluble
form :solid
pka :pKa 4.5/6.9(H2O,t =25.0) (Uncertain)
color :white
optical activity :[α]22/D 35°, c = 0.38 in H2O(lit.)
alpha :D16 -39°
solubility :H2O: soluble
form :solid
pka :pKa 4.5/6.9(H2O,t =25.0) (Uncertain)
color :white
optical activity :[α]22/D 35°, c = 0.38 in H2O(lit.)
Safety Information
| Symbol(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|
